Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2

Abstract

Patients receiving long-term hemodialysis show a reduced antibody response to the first and second doses of the mRNA vaccine BNT162b2. The majority (82%) develop neutralizing antibodies after the second dose but at lower levels than healthy controls.